Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAIL: Atezolizumab in Previously Treated Advanced NSCLC
NCT03285763Phase 4Completed
- Sponsor
- Roche
- Start
- Oct 2017
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 4 trial of atezolizumab in non-small cell lung carcinoma (NSCLC), sponsored by Roche. Started Oct 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03285763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285763.